Nivolumab in Patients With High-Risk Biochemically Recurrent Prostate Cancer

Study Overview

This research study is studying an immune-based cancer drug as a possible treatment for prostate cancer.

The drug involved in this study is:


Study Description

A Phase 2 Study of Nivolumab in Patients with High-Risk Biochemically Recurrent Prostate Cancer

  • Identifier: NCT03637543
  • Protocol Number: 18-249
  • Principal Investigator: David Einstein

Recruitment Status


Contact the research team to learn more about this study.

Fields marked with asterisk (*) are required

Please verify that you are not a bot.

By clicking "Contact Research Team", your contact information will be sent securely to the research staff associated with the study. You will also receive a copy of this email in your inbox, as well as other notifications to determine your participation status in the study.

If you need assistance finding a study or if you have any questions, call us at 617-667-7000